International AIDS Vaccine Initiative
125 Broad St
New York
New York
10004
United States
Tel: 212-847-1111
Fax: 212-847-1112
Website: http://www.iavi.org/
About International AIDS Vaccine Initiative
IAVI is a nonprofit scientific research organization that develops vaccines and antibodies for HIV, tuberculosis, emerging infectious diseases (including COVID-19), and neglected diseases such as snakebite. Our mission is to translate scientific discoveries into affordable, globally accessible public health solutions.
Through scientific and clinical research in Africa, India, Europe, and the U.S., IAVI is pioneering the development of biomedical innovations designed for broad global access. We develop vaccines and antibodies in and for the developing world and seek to accelerate their introduction in low-income countries.
IAVI programs and partnerships are grounded in the regions of the world where the disease burden is the greatest, and our approach emphasizes sustainability. Our network of clinical research center partners in Africa and India helps strengthen in-country research capacity and supports the training and education of the next generation of scientists. The global impact of our science includes fundamental contributions to understanding the biology of HIV infection, which IAVI and others are applying toward advancing vaccine science and immunology.
IAVI accelerates scientific discovery and development by fostering unique collaborations among academia, industry, local communities, governments, and funders to explore new and better ways to address public health threats that disproportionately affect people living in poverty.
Our global reach, including a clinical research network in five countries in sub-Saharan Africa and in India, has allowed us to make fundamental contributions to understanding the epidemiology, transmission, virology, and immunology of HIV. This work played a key role in facilitating the design of promising HIV vaccine candidates, as well as the discovery of broadly neutralizing antibodies that are now being advanced as promising approaches for HIV prevention. Our integrated capabilities in vaccine and antibody discovery, development, and clinical research take advantage of biopharmaceutical industry expertise to accelerate the development of prevention methods and treatments for HIV, tuberculosis, emerging infectious diseases including COVID-19, and snakebite envenoming. Through the Product Development Center, we support external researchers with technical and scientific expertise to accelerate the development of their own products.
46 articles about International AIDS Vaccine Initiative
-
IAVI and Liverpool School of Tropical Medicine to Partner in Scientific Consortium for New Snakebite Therapies
5/16/2019
Partners in five countries will discover and develop monoclonal antibodies to treat critical illness from snake venom, which harms nearly 3 million people each year
-
IAVI Acquires Aeras TB Vaccine Clinical Programs and Assets
10/1/2018
Data from Two Phase II Clinical Trials Conducted by Aeras and Partners Indicate Promise for Future of TB Vaccine Development
-
IAVI and the Public Health Agency of Canada Enter into License Agreement for Technology to Enable Lassa Fever Vaccine Development
8/2/2018
IAVI to Apply Expertise in Viral Vector Vaccines to Lassa Fever Prevention Effort
-
IAVI, Selexis SA and Collaborators Publish Study Highlighting Improved Approach for Generating Complex Proteins Required for Producing HIV Vaccines
5/31/2018
Paper in Frontiers in Immunology Describes Trimer Design and Development of Production CHO Cell Lines That Generate Properly Folded HIV-1 Env Trimers to Support Goal of Developing an Effective HIV Vaccine
-
International AIDS Vaccine Initiative Awarded Grants to Expedite AIDS Vaccine Development
10/3/2016
-
Selexis SA And International AIDS Vaccine Initiative Expand Collaboration to Advance Multiple HIV Vaccine Candidates Toward Clinical Testing
9/22/2016
-
International AIDS Vaccine Initiative Release: New Vaccination Strategies Successfully Coach Immune System To Make Powerful HIV-Neutralizing Antibodies
9/9/2016
-
International AIDS Vaccine Initiative Awarded NIH Contract to Expedite AIDS Vaccine Development
8/9/2016
-
International AIDS Vaccine Initiative Release: Insights Into The Development Of Antibodies That Target A Large Portion Of HIV Strains Could Advance Vaccine Design
5/17/2016
-
International AIDS Vaccine Initiative Names Dr. Mark Feinberg New President And CEO
8/12/2015
-
New Microsphere-Based Methods For Detecting HIV Antibodies, International AIDS Vaccine Initiative Study
5/24/2013
-
International AIDS Vaccine Initiative Welcomes New Members to Board of Directors
7/31/2012
-
International AIDS Vaccine Initiative Welcomes Louis Schwartz as Chief Financial Officer
5/30/2012
-
International AIDS Vaccine Initiative, GlycoMimetics, Inc., and Glycosensors and Diagnostics Collaborate to Develop Novel AIDS Vaccine Candidate
5/9/2012
-
International AIDS Vaccine Initiative and NineSigma Collaborate to Identify New Approaches to Developing AIDS Vaccines
2/21/2012
-
Mary Tydings, Managing Director at Russell Reynolds Associates, Joins International AIDS Vaccine Initiative Board
11/1/2011
-
AIDS Researchers Isolate New Potent and Broadly Effective Antibodies Against HIV, International AIDS Vaccine Initiative, The Scripps Research Institute, Theraclone Sciences, Inc., and Monogram Biosciences Study
8/18/2011
-
International AIDS Vaccine Initiative Appoints Margaret McGlynn President & Chief Executive Officer
7/8/2011
-
Crucell N.V. and Beth Israel Deaconess Medical Center Join Forces with International AIDS Vaccine Initiative to Advance AdVac(R)-based AIDS Vaccine
8/11/2010
-
Senior Merck & Co., Inc. Executive to Head International AIDS Vaccine Initiative’s AIDS Vaccine Design and Development Laboratory
8/10/2010